Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Heron Therapeutics (HRTX) Operating Expenses: 2009-2024

Historic Operating Expenses for Heron Therapeutics (HRTX) over the last 16 years, with Dec 2024 value amounting to $117.2 million.

  • Heron Therapeutics' Operating Expenses rose 9.28% to $30.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $113.0 million, marking a year-over-year decrease of 9.82%. This contributed to the annual value of $117.2 million for FY2024, which is 32.10% down from last year.
  • According to the latest figures from FY2024, Heron Therapeutics' Operating Expenses is $117.2 million, which was down 32.10% from $172.6 million recorded in FY2023.
  • In the past 5 years, Heron Therapeutics' Operating Expenses ranged from a high of $316.8 million in FY2020 and a low of $117.2 million during FY2024.
  • Its 3-year average for Operating Expenses is $172.4 million, with a median of $172.6 million in 2023.
  • Data for Heron Therapeutics' Operating Expenses shows a maximum YoY slumped of 32.10% (in 2024) over the last 5 years.
  • Yearly analysis of 5 years shows Heron Therapeutics' Operating Expenses stood at $316.8 million in 2020, then dropped by 3.99% to $304.2 million in 2021, then declined by 25.22% to $227.5 million in 2022, then dropped by 24.14% to $172.6 million in 2023, then slumped by 32.10% to $117.2 million in 2024.